ReviewPaediatrics & child health2025
Managing newborns at risk for neonatal abstinence syndrome (NAS)/neonatal opioid withdrawal syndrome (NOWS): Updates and emerging best practices.
Review in Paediatrics & child health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Design, implementation, and evaluation of neonatal abstinence syndrome care management web application: a multimethod study.Scientific reports · 2026Trial
- A retrospective cohort study of neonatal abstinence syndrome patients following implementation of Eat Sleep Console Protocol.Paediatrics & child health · 2025Article
- Prevalence of neurodevelopmental disorders in children with chronic hepatitis C in British Columbia.Canadian liver journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of newborns at risk for withdrawal due to antenatal substance exposure has increased rapidly, presenting significant health and early developmental concerns. Access to culturally safer, trauma-informed prenatal care and support for opioid consumption improves health outcomes for both the mother/birthing parent and the fetus. Newborns are at high risk for experiencing symptoms of abstinence or withdrawal that require assessment and non-pharmacological support in the early neonatal period and may go on to require pharmacological treatment. This position statement focuses specifically on women/persons with a substance-exposed pregnancy (SEP) who are taking opioids, their newborns, and the effects of withdrawal and management strategies on newborns. This statement is inclusive of all families, as defined and determined for themselves and representing many structures and identities. Health care team communication, language, and terminology must be culturally safer, trauma-informed, and individualized to meet each family's needs and expressed identity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.